Daniel Chevallard
2021
In 2021, Daniel Chevallard earned a total compensation of $1.7M as Chief Financial Officer, Chief Operating Officer, Secretary at Sunesis Pharmaceuticals, a 163% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $178,543 |
|---|---|
| Option Awards | $663,673 |
| Salary | $425,900 |
| Stock Awards | $394,000 |
| Other | $9,908 |
| Total | $1,672,024 |
Chevallard received $663.7K in option awards, accounting for 40% of the total pay in 2021.
Chevallard also received $178.5K in non-equity incentive plan, $425.9K in salary, $394K in stock awards and $9.9K in other compensation.
Rankings
In 2021, Daniel Chevallard's compensation ranked 6,775th out of 12,415 executives tracked by ExecPay. In other words, Chevallard earned more than 45.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,775 out of 12,415 | 45th |
Division Manufacturing | 2,943 out of 5,505 | 47th |
Major group Chemicals And Allied Products | 1,299 out of 2,375 | 45th |
Industry group Drugs | 1,157 out of 2,096 | 45th |
Industry Pharmaceutical Preparations | 844 out of 1,546 | 45th |
Source: SEC filing on April 27, 2022.
Chevallard's colleagues
We found three more compensation records of executives who worked with Daniel Chevallard at Sunesis Pharmaceuticals in 2021.